{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:59:19Z","timestamp":1789430359157,"version":"build-2803163510"},"reference-count":130,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1016\/j.lpm.2007.11.011","type":"journal-article","created":{"date-parts":[[2008,2,7]],"date-time":"2008-02-07T12:22:43Z","timestamp":1202386963000},"page":"444-459","source":"Crossref","is-referenced-by-count":6,"special_numbering":"P2","title":["Actualit\u00e9s et perspectives th\u00e9rapeutiques du lupus syst\u00e9mique"],"prefix":"10.1016","volume":"37","author":[{"given":"Jean","family":"Sibilia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Pasquali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2007.11.011_bib1","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/art.21039","article-title":"Systemic lupus erythematosus in a multiethnic group: XVI hydroxychloroquine usage is associated with a lower risk of damage accrual","volume":"52","author":"Fessler","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2007.11.011_bib2","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/0961203306071872","article-title":"Effect of anti-malarials on thrombosis and survival in patients with systemic lupus erythematosus","volume":"13","author":"Ruiz-Irastorza","year":"2006","journal-title":"Lupus"},{"key":"10.1016\/j.lpm.2007.11.011_bib3","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.it.2006.06.003","article-title":"TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity","volume":"27","author":"Creagh","year":"2006","journal-title":"Trends Immunol"},{"key":"10.1016\/j.lpm.2007.11.011_bib4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1084\/jem.20041836","article-title":"Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin","volume":"201","author":"Coban","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.lpm.2007.11.011_bib5","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/art.10461","article-title":"Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide","volume":"46","author":"Houssiau","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2007.11.011_bib6","doi-asserted-by":"crossref","first-page":"6573","DOI":"10.4049\/jimmunol.177.10.6573","article-title":"Nucleic acid-sensing TLRs as modifiers of autoimmunity","volume":"177","author":"Deane","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.lpm.2007.11.011_bib7","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1002\/art.22197","article-title":"Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus","volume":"54","author":"Papadimitraki","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2007.11.011_bib8","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/art.21553","article-title":"Toll-like receptor 9 signaling protects against murine lupus","volume":"54","author":"Wu","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2007.11.011_bib9","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.4049\/jimmunol.177.2.1349","article-title":"Role of TLR9 in anti-nucleosome and anti-DNA antibody production in lpr mutation-induced murine lupus","volume":"177","author":"Lartigue","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.lpm.2007.11.011_bib10","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1093\/intimm\/dxl067","article-title":"Toll-like receptor 9-independent aggravation of glomerulonephritis in a novel model of SLE","volume":"18","author":"Yu","year":"2006","journal-title":"Intern Immunol"},{"key":"10.1016\/j.lpm.2007.11.011_bib11","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.4049\/jimmunol.177.4.2088","article-title":"TLR7 ligands induce higher IFN-alpha production in females","volume":"177","author":"Berghofer","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.lpm.2007.11.011_bib12","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1126\/science.1124978","article-title":"Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication","volume":"312","author":"Pisitkum","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.lpm.2007.11.011_bib13","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1002\/art.22157","article-title":"Antimalarial agents: closing the gate on toll-like receptors\u00a0?","volume":"54","author":"Lafyatis","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2007.11.011_bib14","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1002\/art.11304","article-title":"Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group","volume":"48","author":"Costedoat-Chalumeau","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2007.11.011_bib15","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1002\/art.22159","article-title":"Hydroxychloroquine in lupus pregnancy","volume":"54","author":"Clowse","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2007.11.011_bib16","first-page":"1656","article-title":"Concentration-effect relationship of hydroxychloroquine in patients with rheumatoid arthritis--a prospective, dose ranging study","volume":"27","author":"Tett","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1016\/j.lpm.2007.11.011_bib17","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1002\/art.22156","article-title":"Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus","volume":"54","author":"Costedoat-Chalumeau","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2007.11.011_bib18","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1053\/j.ajkd.2003.10.012","article-title":"Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials","volume":"43","author":"Flanc","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.lpm.2007.11.011_bib19","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.4049\/jimmunol.176.6.3311","article-title":"Cutting edge: hormonal milieu, not antigenic specificity, determines the mature phenotype of autoreactive B cells","volume":"176","author":"Venkatesh","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.lpm.2007.11.011_bib20","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.4049\/jimmunol.176.5.2703","article-title":"Hormonal Regulation of B Cell Development: 17beta-Estradiol Impairs Negative Selection of High-Affinity DNA-Reactive B Cells at More Than One Developmental Checkpoint","volume":"176","author":"Grimaldi","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.lpm.2007.11.011_bib21","doi-asserted-by":"crossref","first-page":"6352","DOI":"10.4049\/jimmunol.179.9.6352","article-title":"Demethylation of CD40LG on the inactive X in T cells from women with lupus","volume":"179","author":"Lu","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.lpm.2007.11.011_bib22","doi-asserted-by":"crossref","first-page":"9970","DOI":"10.1073\/pnas.0603912103","article-title":"A Tlr7 translocation accelerates systemic autoimmunity in murine lupus","volume":"103","author":"Subramanian","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.lpm.2007.11.011_bib23","doi-asserted-by":"crossref","first-page":"953","DOI":"10.7326\/0003-4819-142-12_Part_1-200506210-00004","article-title":"The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial","volume":"142","author":"Buyon","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.lpm.2007.11.011_bib24","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1056\/NEJMoa050817","article-title":"A trial of contraceptive methods in women with systemic lupus erythematosus","volume":"353","author":"Sanchez-Guerrero","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2007.11.011_bib25","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa051135","article-title":"Combined oral contraceptives in women with systemic lupus erythematosus","volume":"353","author":"Petri","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2007.11.011_bib26","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1056\/NEJMe058269","article-title":"Oral contraceptives in systemic lupus erythematosus \u2013 a tough pill to swallow\u00a0?","volume":"353","author":"Bermas","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2007.11.011_bib27","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/art.10364","article-title":"Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial","volume":"46","author":"Petri","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2007.11.011_bib28","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1002\/art.1780381216","article-title":"Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double-blind, placebo-controlled, randomized clinical trial","volume":"38","author":"van Vollenhoven","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2007.11.011_bib29","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/art.1780370906","article-title":"An open study of dehydroepiandrosterone in systemic lupus erythematosus","volume":"37","author":"van Vollenhoven","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2007.11.011_bib30","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1002\/art.20427","article-title":"Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus","volume":"50","author":"Petri","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2007.11.011_bib31","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1056\/NEJM200010193431604","article-title":"Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis","volume":"343","author":"Chan","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2007.11.011_bib32","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa043731","article-title":"Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis","volume":"353","author":"Ginzler","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2007.11.011_bib33","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1440-1797.2005.00444.x","article-title":"Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis","volume":"10","author":"Ong","year":"2005","journal-title":"Nephrology"},{"key":"10.1016\/j.lpm.2007.11.011_bib34","first-page":"705","article-title":"Mycophenolate mofetil versus cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis","volume":"115","author":"Hu","year":"2002","journal-title":"Chin Med J"},{"key":"10.1016\/j.lpm.2007.11.011_bib35","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1056\/NEJMoa031855","article-title":"Sequential therapies for proliferative lupus nephritis","volume":"350","author":"Contreras","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2007.11.011_bib36","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1681\/ASN.2004080686","article-title":"Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis","volume":"16","author":"Chan","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.lpm.2007.11.011_bib37","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/j.1523-1755.2005.00461.x","article-title":"Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study","volume":"68","author":"Mok","year":"2005","journal-title":"Kidney Int"},{"issue":"suppl","key":"10.1016\/j.lpm.2007.11.011_bib38","article-title":"Rapamycin reduces disease activity and normalizes T-cell activation-induced calcium fluxing in patients with systemic lupus erythematosus","volume":"54","author":"Fernandez","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2007.11.011_bib39","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1191\/0961203305lu2136oa","article-title":"Block and tackle: CTLA4Ig takes on lupus","volume":"14","author":"Davidson","year":"2005","journal-title":"Lupus"},{"key":"10.1016\/j.lpm.2007.11.011_bib40","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.4049\/jimmunol.177.7.4481","article-title":"B cells drive early T cell autoimmunity in vivo prior to dendritic cell-mediated autoantigen presentation","volume":"177","author":"Yan","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.lpm.2007.11.011_bib41","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/01.bor.0000172798.26249.fc","article-title":"Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future","volume":"17","author":"Sfikakis","year":"2005","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.lpm.2007.11.011_bib42","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/ard.2004.029694","article-title":"Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases","volume":"64","author":"Gottenberg","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"suppl","key":"10.1016\/j.lpm.2007.11.011_bib43","article-title":"Major clinical responses in severe SLE following treatment with rituximab plus cyclophosphamide are predicted by lower baseline CD19 lymphocyte count and creater changes in IgA anti-DNA","volume":"54","author":"Jonsdottir","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2007.11.011_bib44","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1002\/art.22046","article-title":"Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis","volume":"54","author":"Smith","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2007.11.011_bib45","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1136\/ard.2005.044487","article-title":"Repeated B cell depletion in treatment of refractory systemic lupus erythematosus","volume":"65","author":"Ng","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2007.11.011_bib46","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1093\/rheumatology\/kei080","article-title":"B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients","volume":"44","author":"Leandro","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.lpm.2007.11.011_bib47","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/art.10764","article-title":"The relation ship of Fc\u03b3R IIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus","volume":"48","author":"Anolik","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2007.11.011_bib48","first-page":"642","article-title":"Role of complement in innate and autoimmunity","volume":"18","author":"Sielen","year":"2005","journal-title":"J Nephrol"},{"key":"10.1016\/j.lpm.2007.11.011_bib49","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1002\/art.22211","article-title":"B cell depletion therapy in systemic lupus erythematosus","volume":"54","author":"Cambridge","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"suppl","key":"10.1016\/j.lpm.2007.11.011_bib50","article-title":"Response to immunization in SLE patients treated with rituximab","volume":"54","author":"Albert","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2007.11.011_bib51","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/art.20430","article-title":"B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I\/II dose-escalation trial of rituximab","volume":"50","author":"Looney","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2007.11.011_bib52","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1002\/art.20592","article-title":"Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus","volume":"50","author":"Anolik","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"suppl","key":"10.1016\/j.lpm.2007.11.011_bib53","article-title":"B cell reconstitution after rituximab recapitulates B cell ontogeny with a preponderance of transitional B cells and a paucity of memory B cells","volume":"54","author":"Anolik","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2007.11.011_bib54","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/art.20858","article-title":"Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial","volume":"52","author":"Sfikakis","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2007.11.011_bib55","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/rheumatology\/keh443","article-title":"Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab","volume":"44","author":"Tokunaga","year":"2005","journal-title":"Rheumatology"},{"key":"10.1016\/j.lpm.2007.11.011_bib56","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/art.22545","article-title":"Progressive multifocal leukoencephalopathy in systemic lupus erythematosus","volume":"57","author":"Govindappa","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2007.11.011_bib57","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/art.21721","article-title":"Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus","volume":"54","author":"Itoh","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2007.11.011_bib58","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/rheumatology\/keh533","article-title":"Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab","volume":"44","author":"Tahir","year":"2005","journal-title":"Rheumatology"},{"issue":"suppl","key":"10.1016\/j.lpm.2007.11.011_bib59","article-title":"TRU-015 a small modular immunopharmaceutical (SMIPTM) drug candidate directed against CD20, demonstrates clinical improvement in subjects with rheumatoid arthritis","volume":"54","author":"Burge","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2007.11.011_bib60","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1182\/blood-2002-07-1952","article-title":"Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies","volume":"101","author":"Faderl","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2007.11.011_bib61","first-page":"39825","article-title":"Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties","volume":"9","author":"Carnahan","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lpm.2007.11.011_bib62","doi-asserted-by":"crossref","first-page":"R74","DOI":"10.1186\/ar1942","article-title":"Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus","volume":"8","author":"D\u00f6rner","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.lpm.2007.11.011_bib63","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1177\/0961203306071871","article-title":"B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time","volume":"15","author":"Becker-Merok","year":"2006","journal-title":"Lupus"},{"key":"10.1016\/j.lpm.2007.11.011_bib64","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1002\/art.11299","article-title":"Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator","volume":"48","author":"Baker","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"suppl","key":"10.1016\/j.lpm.2007.11.011_bib65","article-title":"Belimumab (BmAb) reduces SLE disease activity and demonstrates durable bioactivity at 76 weeks","volume":"54","author":"Wallace","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"suppl","key":"10.1016\/j.lpm.2007.11.011_bib66","article-title":"BR3-Fc phase I study: safety, pharmacokinetics (PK) and pharmacodynamic (PD) effects of a novel BR3-Fc fusion protein in patients with rheumatoid arthritis","volume":"54","author":"Fleischmann","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"suppl","key":"10.1016\/j.lpm.2007.11.011_bib67","first-page":"LB19","article-title":"Trial of atacicept in patients with systemic lupus erythematosus (SLE)","volume":"54","author":"Dall\u2019Era","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2007.11.011_bib68","first-page":"257","article-title":"Treatment of systemic lupus erythematosus with LJP 394","volume":"28","author":"Furie","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.lpm.2007.11.011_bib69","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/art.10763","article-title":"LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study","volume":"48","author":"Alarcon-Segovia","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2007.11.011_bib70","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1191\/0961203303lu440oa","article-title":"Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo","volume":"12","author":"Strand","year":"2003","journal-title":"Lupus"},{"key":"10.1016\/j.lpm.2007.11.011_bib71","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1191\/096120301671920760","article-title":"Apheresis for lupus erythematosus: state of the art","volume":"10","author":"Wallace","year":"2001","journal-title":"Lupus"},{"key":"10.1016\/j.lpm.2007.11.011_bib72","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1126\/science.307.5711.835","article-title":"Drug development. Lupus drug company asks FDA for second chance","volume":"307","author":"Couzin","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.lpm.2007.11.011_bib73","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1073\/pnas.0337679100","article-title":"Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus","volume":"100","author":"Baechler","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.lpm.2007.11.011_bib74","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1002\/art.20798","article-title":"Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus","volume":"50","author":"Kirou","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2007.11.011_bib75","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1073\/pnas.0510837103","article-title":"Activation of interferon pathways and plasmacytoid dendritic cell recruitment in target organs from patients with primary Sj\u00f6gren's syndrome","volume":"108","author":"Gottenberg","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.lpm.2007.11.011_bib76","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/art.21031","article-title":"Activation of the interferon-\u03b1 pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease","volume":"52","author":"Kirou","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2007.11.011_bib77","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1002\/art.20508","article-title":"Interferon-\u03b1-inductible proteins are novel autoantigens in murine lupus","volume":"50","author":"Hueber","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2007.11.011_bib78","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1172\/JCI23025","article-title":"Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9","volume":"115","author":"Means","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.lpm.2007.11.011_bib79","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1002\/art.21893","article-title":"Induction of interferon-\u03b1 by immune complexes or liposomes containing systemic lupus erythematosus autoantigen-and Sj\u00f6gren's syndrome autoantigen-associated RNA","volume":"54","author":"L\u00f6vgren","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2007.11.011_bib80","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1002\/art.21307","article-title":"Deficiency of type I interferon contributes to Sle2-associated component lupus phenotypes","volume":"52","author":"Li","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2007.11.011_bib81","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1681\/ASN.2004111014","article-title":"Interferon-beta: a therapeutic for autoimmune lupus in MRL-Faslpr mice","volume":"16","author":"Schwarting","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.lpm.2007.11.011_bib82","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.4049\/jimmunol.173.3.2134","article-title":"Type I IFN protects against murine lupus","volume":"173","author":"Hron","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.lpm.2007.11.011_bib83","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1084\/jem.20021996","article-title":"Type 1 interferon receptor deficiency reduces lupus-like disease in NZB mice","volume":"197","author":"Santiago-Raber","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.lpm.2007.11.011_bib84","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1517\/13543776.16.2.221","article-title":"Human monoclonal antibodies to IFN-\u03b1 for the treatment of autoimmune diseases","volume":"16","author":"Medarex","year":"2006","journal-title":"Expert Opin Ther Patents"},{"issue":"897","key":"10.1016\/j.lpm.2007.11.011_bib85","first-page":"e1-897-e6","article-title":"TLR9-based immunotherapy for allergic disease","volume":"119","author":"Hayashi","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.lpm.2007.11.011_bib86","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMoa052916","article-title":"Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis","volume":"355","author":"Creticos","year":"2006","journal-title":"New Engl J Med"},{"key":"10.1016\/j.lpm.2007.11.011_bib87","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0140-6736(06)69210-6","article-title":"Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: adouble-blind randomised trial","volume":"361","author":"Vanags","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2007.11.011_bib88","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.0105-2896.2004.00202.x","article-title":"Is targeting toll-like receptors and their signalling pathway a useful therapeutic approach to modulating cytokine-driven inflammation\u00a0?","volume":"202","author":"Andreakos","year":"2004","journal-title":"Immunol Rev"},{"key":"10.1016\/j.lpm.2007.11.011_bib89","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1073\/pnas.98.3.1148","article-title":"The mechanism by which a peptide based on complementarity-determining region-1 of a pathogenic anti-DNA auto-Ab ameliorates experimental systemic lupus erythematosus","volume":"98","author":"Eilat","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.lpm.2007.11.011_bib90","doi-asserted-by":"crossref","first-page":"5839","DOI":"10.4049\/jimmunol.175.9.5839","article-title":"Selective modulation of CD4+ T cells from lupus patients by a promiscuous, protective peptide analog","volume":"175","author":"Monneaux","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.lpm.2007.11.011_bib91","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1002\/art.20520","article-title":"Treatment of murine lupus using nucleosomal T cell epitopes identified by bone marrow-derived dendritic cells","volume":"50","author":"Suen","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2007.11.011_bib92","doi-asserted-by":"crossref","first-page":"8810","DOI":"10.1073\/pnas.0603201103","article-title":"A peptide based on the complementarity-determining region 1 of an autoantibody ameliorates lupus by up-regulating CD4+CD25+ cells and TGF-\u03b2","volume":"103","author":"Sharabi","year":"2006","journal-title":"PNAS"},{"key":"10.1016\/j.lpm.2007.11.011_bib93","doi-asserted-by":"crossref","first-page":"7255","DOI":"10.4049\/jimmunol.175.11.7255","article-title":"The inhibition of autoreactive T cell functions by a peptide based on the CDR1 of an anti-DNA autoantibody is via TGF-beta-mediated suppression of LFA-1 and CD44 expression and function","volume":"175","author":"Sela","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.lpm.2007.11.011_bib94","doi-asserted-by":"crossref","first-page":"7728","DOI":"10.4049\/jimmunol.175.11.7728","article-title":"Tolerogenic treatment of lupus mice with consensus peptide induces Foxp3-expressing, apoptosis-resistant, TGFbeta-secreting CD8+T cell suppressors","volume":"175","author":"Hahn","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.lpm.2007.11.011_bib95","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.clim.2006.01.007","article-title":"Amelioration of murine lupus by a peptide, based on the complementarity determining region-1 of an autoantibody as compared to dexamethasone: different effects on cytokines and apoptosis","volume":"119","author":"Sharabi","year":"2006","journal-title":"Clin Immunol"},{"key":"10.1016\/j.lpm.2007.11.011_bib96","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.lpm.2007.11.011_bib97","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.4049\/jimmunol.175.8.5516","article-title":"Treatment with a laminin-derived peptide suppresses lupus nephritis","volume":"175","author":"Amital","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.lpm.2007.11.011_bib98","doi-asserted-by":"crossref","first-page":"6959","DOI":"10.4049\/jimmunol.175.10.6959","article-title":"A mimic of p21WAF1\/CIP1 ameliorates murine lupus","volume":"175","author":"Goulvestre","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.lpm.2007.11.011_bib99","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1002\/art.20576","article-title":"Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study","volume":"50","author":"Aringer","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2007.11.011_bib100","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/art.20851","article-title":"The intracellular 52-kd Ro\/SSA autoantigen in keratinocytes is up-regulated by tumor necrosis factor alpha via tumor necrosis factor receptor I","volume":"52","author":"Gerl","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2007.11.011_bib101","doi-asserted-by":"crossref","first-page":"383","DOI":"10.4049\/jimmunol.177.1.383","article-title":"Characterization of human complement receptor type 2 (CR2\/CD21) as a receptor for IFN-alpha: a potential role in systemic lupus erythematosus","volume":"177","author":"Szakonyi","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.lpm.2007.11.011_bib102","doi-asserted-by":"crossref","first-page":"8563","DOI":"10.1073\/pnas.93.16.8563","article-title":"Amelioration of lupus like autoimmune disease in NZB\/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5","volume":"93","author":"Wang","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.lpm.2007.11.011_bib103","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"New Engl J Med"},{"key":"10.1016\/j.lpm.2007.11.011_bib104","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.4049\/jimmunol.175.3.1947","article-title":"Signaling through up-regulated C3a receptor is key to the development of experimental lupus nephritis","volume":"175","author":"Bao","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.lpm.2007.11.011_bib105","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1002\/eji.200526327","article-title":"C5a promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist","volume":"35","author":"Bao","year":"2005","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.lpm.2007.11.011_bib106","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.4049\/jimmunol.168.7.3601","article-title":"Transgenic expression of a soluble complement inhibitor protects againts renal disease and promotes survival in MRL\/Lpr mice","volume":"168","author":"Bao","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.lpm.2007.11.011_bib107","first-page":"166","article-title":"Complement C3 activation is required for anti-phospholipid antibody-induced fetal loss","volume":"178","author":"Holers","year":"2002","journal-title":"J Exp Med"},{"key":"10.1016\/j.lpm.2007.11.011_bib108","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1126\/science.287.5452.498","article-title":"A critical role for murine complement regulator crry in fetomaternal tolerance","volume":"287","author":"Xu","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.lpm.2007.11.011_bib109","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S1521-6616(03)00034-2","article-title":"The complement system as a therapeutic target in autoimmunity","volume":"107","author":"Holers","year":"2003","journal-title":"Clin Immunol"},{"key":"10.1016\/j.lpm.2007.11.011_bib110","doi-asserted-by":"crossref","first-page":"5540","DOI":"10.4049\/jimmunol.173.9.5540","article-title":"Complement inactivation by recombinant human C3 derivatives","volume":"173","author":"Kolln","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.lpm.2007.11.011_bib111","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/nm1121","article-title":"Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation","volume":"10","author":"Girardi","year":"2004","journal-title":"Nat Med"},{"issue":"suppl","key":"10.1016\/j.lpm.2007.11.011_bib112","article-title":"Proteasome inhibition for treatment of lupus in NZB\/W mice","volume":"54","author":"Neubert","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2007.11.011_bib113","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1126\/science.1105160","article-title":"Restoration of tolerance in lupus by targeted inhibitory receptor expression","volume":"307","author":"McGaha","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.lpm.2007.11.011_bib114","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/nm1291","article-title":"PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus","volume":"11","author":"Barber","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.lpm.2007.11.011_bib115","doi-asserted-by":"crossref","first-page":"589","DOI":"10.4049\/jimmunol.176.1.589","article-title":"Class IB-phosphatidylinositol 3-kinase (PI3K) deficiency ameliorates IA-PI3K-induced systemic lupus but not T cell invasion","volume":"176","author":"Barber","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.lpm.2007.11.011_bib116","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1002\/art.21424","article-title":"Amelioration of autoimmune nephritis by imatinib in MRL\/lpr mice","volume":"52","author":"Sadanaga","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2007.11.011_bib117","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/art.21556","article-title":"Prevention and reversal of nephritis in MRL\/lpr mice with a single injection of C-reactive protein","volume":"54","author":"Rodriguez","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"suppl.","key":"10.1016\/j.lpm.2007.11.011_bib118","article-title":"C-reactive protein regulates the interferon response to immune complexes containing snRNPs","volume":"54","author":"Mold","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2007.11.011_bib119","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nm1005","article-title":"Human lupus T cells resist inactivation and escape death by upregulating COX-2","volume":"10","author":"Xu","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.lpm.2007.11.011_bib120","doi-asserted-by":"crossref","first-page":"4999","DOI":"10.4049\/jimmunol.175.8.4999","article-title":"Chronic morphine treatment promotes specific Th2 cytokine production by murine T cells in vitro via a Fas\/Fas ligand-dependent mechanism","volume":"175","author":"Greeneltch","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.lpm.2007.11.011_bib121","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/jama.295.5.527","article-title":"Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus","volume":"295","author":"Burt","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.lpm.2007.11.011_bib122","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1182\/blood-2005-07-2800","article-title":"Autologous stem cell transplantation for autoimmunity induces immunologic self-tolerance by reprogramming autoreactive T cells and restoring the CD4+CD25+ immune regulatory network","volume":"107","author":"de Kleer","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2007.11.011_bib123","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/ncpcardio0270","article-title":"Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease","volume":"2","author":"Haque","year":"2005","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.lpm.2007.11.011_bib124","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa035471","article-title":"Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus","volume":"349","author":"Roman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2007.11.011_bib125","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1191\/0961203303lu2135oa","article-title":"Statins: immunomodulators for autoimmune rheumatic disease?","volume":"14","author":"Jury","year":"2005","journal-title":"Lupus"},{"key":"10.1016\/j.lpm.2007.11.011_bib126","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.4049\/jimmunol.177.5.3028","article-title":"Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model","volume":"177","author":"Aprahamian","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.lpm.2007.11.011_bib127","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1056\/NEJMoa033122","article-title":"Mannose-binding lectin variant alleles and the risk of arterial thrombosis in systemic lupus erythematosus","volume":"351","author":"Ohlenschlaeger","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2007.11.011_bib128","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1191\/0961203303lu1055oa","article-title":"Antibodies to mannose binding lectin in patients with systemic lupus erythematosus","volume":"13","author":"Mok","year":"2004","journal-title":"Lupus"},{"key":"10.1016\/j.lpm.2007.11.011_bib129","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1042\/bst0310770","article-title":"Clinical potential of mannose-binding lectin-replacement therapy","volume":"31","author":"Summerfield","year":"2003","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.lpm.2007.11.011_bib130","article-title":"EULAR recommendations for the management of Systemic Lupus Erytematosus (SLE). Report of a Task Force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)","author":"Bertsias","year":"2007","journal-title":"Ann Rheum Dis"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498207008329?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498207008329?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T23:00:17Z","timestamp":1557270017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498207008329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":130,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["S0755498207008329"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2007.11.011","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}